Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 100

Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA

Dr Yana Pikman speaks to ecancer at ASH 2018 about the LEAP consortium and targeted therapy for paediatric leukaemia patients.

She explains that there are a number of genomic changes in paediatric leukaemia patients that could be targeted, with 13% of patients showing these changes in the study.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation